<DOC>
	<DOCNO>NCT02213367</DOCNO>
	<brief_summary>Chronic spontaneous urticaria ( CSU ) , formerly also know chronic idiopathic urticaria chronic urticaria ( CU ) , one frequent skin disease . At time , 0.5-1 % population suffers disease . Although age group affect , peak incidence see 20 40 year age . The duration disease generally several year likely longer severe case , case concurrent angioedema , combination physical urticaria positive autologous serum skin test ( autoreactivity ) . CSU major detrimental effect quality life , sleep deprivation psychiatric comorbidity frequent . It also large impact society term direct indirect health care cost well reduced performance work private life .</brief_summary>
	<brief_title>Bilastine Updosing Chronic Spontaneous Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<criteria>Male female age 18 year old History active chronic spontaneous urticaria without associate angioedema least three day per week last 6 week prior visit 1 . Urticaria symptom must comprise wheal itch History fail treatment antihistamine bilastine standard ( license ) dose . UAS7 ≥14 baseline Informed consent sign date Able read , understand willing sign inform consent form abide study procedure Willing , commit able return clinic visit complete studyrelated procedure In female childbearing potential : negative pregnancy test ; female willing use highly effective contraception ( PearlIndex &lt; 1 ) woman consider childbearing potential postmenopausal &gt; 2 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) No participation clinical trial 4 week participation study Chronic spontaneous urticaria patient know resistance bilastine Isolated presence domination inducible form urticaria cholinergic urticaria ( chronic spontaneous urticaria ) History adverse reaction bilastine know hypersensitivity bilastine ingredient Intake oral corticosteroid intravenously apply corticosteroid within 28 day prior screen visit Use depot corticosteroid within 3 month prior screen visit ( inhaled corticosteroid allow ) Use systemic immunosupressants/immunomodulators ciclosporin , dapsone , metotrexate , comparable drug within 28 day prior screen visit . Use UVtherapy within 28 day prior visit 1 Significant medical condition , opinion Investigator , render patient immunocompromised suitable clinical trial Significant concomitant illness , opinion Investigator , would adversely affect subject 's participation evaluation study ECG alteration repolarisation ( QTc prolongation &gt; 450ms increase QTc &gt; 60ms compare baseline assessment ) Blood pressure &gt; 180/100 mmHg and/or heart rate &gt; 100/min Evidence significant hepatic renal disease ( GOT and/or GPT &gt; 2 time upper reference value , serum creatinine 1.5 time upper reference value ) Subjects concern , opinion Investigator , compliance protocol procedures The presence permanent gastrointestinal condition may influence oral therapy ( chronic diarrhoea disease , congenital malformation surgical mutilation gastrointestinal tract ) Presence active cancer require chemotherapy radiation therapy Presence alcohol abuse drug addiction Pregnancy breastfeed Subjects inmates psychiatric ward , prison , state institution . Existing plan placement institution rule accord § 40 passage 1 , number 4 AMG ( Arzneimittelgesetz ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>